Annual report
9776.TEDINET S100OJXV
Period2021-04-01 → 2022-03-31
Filed2022-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥17.5bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥17.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.1bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.5bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥1.1bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥983m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥813m | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.5bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.2bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥794m | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥528m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥523m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥685m | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥794m | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥16.1bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥14.5bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥11.6bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥10.7bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥10.6bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.8bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥5.2bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.3bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.5bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥7.6bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.4bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.0bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥838m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥647m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.3bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥831m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥80m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥293m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥113m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.9bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥52m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥146m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥95m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥306.16 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥231.85 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.3 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥152.42 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥197.03 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,016.24 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,708.63 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,472.23 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,331.49 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,194.08 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.9% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.7% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.7% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 10.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.0% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.4% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 871 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 819 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 820 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 810 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 781 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥17.7bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥16.4bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥16.5bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥16.0bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥16.4bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.5bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥1.1bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.2bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥944m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥758m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥998m | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.5bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.2bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.0bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥791m | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥503m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥487m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥650m | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥14.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥13.7bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥10.7bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥9.9bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥9.9bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥4.6bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥4.6bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥9.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥9.0bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.2bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥7.8bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.4bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.0bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥300.67 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥231.1 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.04 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥141.84 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥186.8 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥23 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥23 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥11 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,934.15 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,633.22 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,398.25 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,264.33 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,137.75 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 68.1% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.0% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.0% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.7% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.9% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.4% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.1% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,216,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 622 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 775 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 779 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 774 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 747 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 86
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-04-01 → 2022-03-31 | ¥8m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥138,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 2 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥103m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥102m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥906,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥24m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥71m |
| Clinical Testing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Clinical Testing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥324m |
| Clinical Testing Businessreportable segment | employees | at 2022-03-31 | 528 pure |
| Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥7.4bn |
| Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥7.4bn |
| Clinical Testing Businessreportable segment | segment assets | at 2022-03-31 | ¥4.3bn |
| Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥149m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥87m |
| Dispensing Pharmacy Businessreportable segment | employees | at 2022-03-31 | 297 pure |
| Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥10.6bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥10.6bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2022-03-31 | ¥3.3bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥879m |
| Medical Devices Sales And Maintenance Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥4m |
| Medical Devices Sales And Maintenance Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥8m |
| Medical Devices Sales And Maintenance Businessreportable segment | employees | at 2022-03-31 | 20 pure |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥984m |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| Medical Devices Sales And Maintenance Businessreportable segment | segment assets | at 2022-03-31 | ¥816m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥10m |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥1.6bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥420m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥20.2bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥19.0bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| —segment total | segment assets | at 2022-03-31 | ¥8.4bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥420m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥20.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥19.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥8.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2020-04-01 → 2021-03-31 | ¥213,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2020-04-01 → 2021-03-31 | ¥87m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2020-04-01 → 2021-03-31 | ¥86m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥721,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2021-03-31 | ¥13m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2020-04-01 → 2021-03-31 | ¥66m |
| Clinical Testing Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥312m |
| Clinical Testing Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥158m |
| Clinical Testing Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥6.1bn |
| Clinical Testing Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥6.1bn |
| Clinical Testing Businessreportable segment | segment assets | at 2021-03-31 | ¥2.5bn |
| Clinical Testing Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥625m |
| Dispensing Pharmacy Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥111m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥85m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥10.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥10.4bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2021-03-31 | ¥3.3bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥863m |
| Medical Devices Sales And Maintenance Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥5m |
| Medical Devices Sales And Maintenance Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥8m |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥1.5bn |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥836m |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥652m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment assets | at 2021-03-31 | ¥836m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | −¥1m |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥429m |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥251m |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥18.1bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥17.4bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥652m |
| —segment total | segment assets | at 2021-03-31 | ¥6.7bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥429m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥251m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥18.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥653m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 2 pure |
| Clinical Testing Businessreportable segment | employees | at 2022-03-31 | 299 pure |
| Dispensing Pharmacy Businessreportable segment | employees | at 2022-03-31 | 297 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,457
| Item | Context | Value | Unit |
|---|---|---|---|
| Non operating income | CurrentYearDuration | 134997000 | JPY |
| Interest expenses noe | Prior1YearDuration | 2575000 | JPY |
| Interest expenses noe | CurrentYearDuration | 9027000 | JPY |
| Cost of lease revenue noe | Prior1YearDuration | 46354000 | JPY |
| Cost of lease revenue noe | CurrentYearDuration | 50749000 | JPY |
| Other noe | Prior1YearDuration | 7468000 | JPY |
| Other noe | CurrentYearDuration | 6827000 | JPY |
| Non operating expenses | Prior1YearDuration | 56398000 | JPY |
| Non operating expenses | CurrentYearDuration | 66604000 | JPY |
| Ordinary income | Prior1YearDuration | 1188144000 | JPY |
| Ordinary income | CurrentYearDuration | 1605618000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YearDuration | 413000 | JPY |
| Gain on sales of noncurrent assets ei | CurrentYearDuration | 11429000 | JPY |
| Extraordinary income | Prior1YearDuration | 413000 | JPY |
| Extraordinary income | CurrentYearDuration | 11429000 | JPY |
| Loss on sales of noncurrent assets el | Prior1YearDuration | － | JPY |
| Loss on sales of noncurrent assets el | CurrentYearDuration | 10960000 | JPY |
| Loss on retirement of noncurrent assets el | Prior1YearDuration | 895000 | JPY |
| Loss on retirement of noncurrent assets el | CurrentYearDuration | 906000 | JPY |
| Loss on valuation of investment securities el | Prior1YearDuration | 11735000 | JPY |
| Loss on valuation of investment securities el | CurrentYearDuration | － | JPY |
| Impairment loss el | Prior1YearDuration | － | JPY |
| Impairment loss el | CurrentYearDuration | 28552000 | JPY |
| Head office transfer cost el | Prior1YearDuration | － | JPY |
| Head office transfer cost el | CurrentYearDuration | 74486000 | JPY |
| Extraordinary loss | Prior1YearDuration | 12630000 | JPY |
| Extraordinary loss | CurrentYearDuration | 114905000 | JPY |
| Income before income taxes | Prior1YearDuration | 1175928000 | JPY |
| Income before income taxes | CurrentYearDuration | 1502142000 | JPY |
| Income taxes current | Prior1YearDuration | 377282000 | JPY |
| Income taxes current | CurrentYearDuration | 451902000 | JPY |
| Income taxes deferred | Prior1YearDuration | 4957000 | JPY |
| Income taxes deferred | CurrentYearDuration | 3699000 | JPY |
| Income taxes | Prior1YearDuration | 382239000 | JPY |
| Income taxes | CurrentYearDuration | 455601000 | JPY |
| Profit loss | Prior1YearDuration | 793688000 | JPY |
| Profit loss | CurrentYearDuration | 1046541000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YearDuration | － | JPY |
| Profit loss attributable to non controlling interests | CurrentYearDuration | 3659000 | JPY |
| Profit loss attributable to owners of parent | Prior1YearDuration | 793688000 | JPY |
| Profit loss attributable to owners of parent | CurrentYearDuration | 1042882000 | JPY |
| Profit loss | Prior1YearDuration | 793688000 | JPY |
| Profit loss | CurrentYearDuration | 1046541000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YearDuration | 49783000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYearDuration | -27201000 | JPY |
| Other comprehensive income | Prior1YearDuration | 49783000 | JPY |
| Other comprehensive income | CurrentYearDuration | -27201000 | JPY |
| Comprehensive income | Prior1YearDuration | 843471000 | JPY |
| Comprehensive income | CurrentYearDuration | 1019339000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YearDuration | 843471000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |